Sarepta Therapeutics, Inc.
SRPT · Nasdaq
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.86B | $1.79B | $1.14B | $843.77M | $612.40M | $455.87M | $380.83M | $301.03M |
| Cost of Revenue | $25.50M | — | — | — | — | — | — | — |
| Research & Development | — | — | — | — | — | — | — | $401.84M |
| Selling, General & Administrative | $491.72M | $557.87M | $481.87M | $451.42M | $282.66M | $317.88M | $284.81M | $207.76M |
| Operating Expenses | $2.90B | $1.68B | $1.51B | $1.47B | $1.16B | $1.10B | $1.09B | $644.66M |
| Operating Income | -$699.78M | $218.08M | -$267.82M | -$536.20M | -$459.71M | -$564.16M | -$705.56M | -$343.63M |
| Interest Expense | -$38.14M | -$18.39M | -$22.01M | -$53.25M | $63.52M | $59.95M | $30.67M | $33.71M |
| Other Income / (Expense) | -$2.44M | $42.69M | -$252.27M | -$153.76M | $40.76M | $11.10M | -$8.32M | -$18.98M |
| Income Before Taxes | -$702.23M | $260.77M | -$520.10M | -$689.96M | -$418.95M | -$553.07M | -$713.88M | -$362.61M |
| Provision for Income Taxes | $11.19M | $25.54M | $15.88M | $13.53M | -$168.00K | $1.06M | $1.20M | -$692.00K |
| Net Income | -$713.41M | $235.24M | -$535.98M | -$703.49M | -$418.78M | -$554.13M | -$715.08M | -$361.92M |
| Basic EPS | -$7.13 | $2.47 | -$5.80 | -$8.03 | -$5.15 | -$7.11 | — | — |
| Diluted EPS | -$7.13 | $2.34 | -$5.80 | -$8.03 | -$5.15 | -$7.11 | — | — |
| Basic Shares Outstanding | 100.12M | 95.08M | 92.40M | 87.56M | 81.26M | 77.96M | 73.61M | 66.25M |
| Diluted Shares Outstanding | 100.12M | 107.88M | 92.40M | 87.56M | 81.26M | 77.96M | 73.61M | 66.25M |
Analyst Estimates
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $3.27 | $2.20 | $4.61 | 4 | ↑0 ↓1 |
| Dec 2027 | $1.34 | -$0.19 | $3.51 | 5 | ↑0 ↓1 |
| Dec 2028 | $1.09 | -$0.24 | $2.70 | 4 | ↑0 ↓0 |
| Dec 2029 | -$0.14 | -$0.14 | -$0.14 | 1 | ↑0 ↓0 |
